Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, Goncalves B, Zheng Q, Mou H, Yang J, Huang L, Miao F, Zeng T, Karakousis G, Huang AC, Mitchell T, Amaravadi R, Schuchter L, Milone M, Guo W, June C, Herlyn M, Fan Y, Xu X DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity , Molecular Therapy , 34(3): 2026
Messing I, Linkowski L, Riina MD, Berger M, Baron J, Wang X, Kallan M, Hubbeling HG, Lustig RA, Dorsey JF, Kurtz G, Nagda S, Lukens JN, Flowers A, Lee JYK, Amankulor NM, Jackson C, Mohan S, Amaravadi RK, Schuchter LM, Huang AC, Mitchell TC, Alonso-Basanta M, Lebow ES Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy. , Oncologist, 31(4): 2026
Park SL, Painter MM, Manne S, Alcalde V, McLaughlin M, Sullivan MA, Mathew D, Torres L, Huang YJ, Reeg DB, Douek NR, Campos T, Klapholz M, Cardenas MA, Fang V, Ngiow SF, Kc W, Goel RR, Baxter AE, Wu JE, Tan M, Berry CT, Ellebrecht CT, Huang AC, Papazian E, Liu Y, Rajasekaran K, Brody RM, Thaler ER, Basu D, Diab A, Giles JR, Wherry EJ Tissue-resident exhausted and memory CD8(+) T cells have distinct ontogeny, function and role in disease , Nature Immunology, 27(1): 2026
Lucas MW, Burton EM, Dimitriadis P, Huang AC, Long GV, Mitchell TC, Amaria RN, Blank CU Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity , Immunity, 59(1): 2026
Wang G, Yoon D, Nandi A, Patel K, Azar T, Kim J, Han NA, Nickie A, Park S, Wang K, Yan P, Divaker S, Tabita-Martinez J, Giles L, Carberry M, Beltra JC, Painter MM, Alanio C, Amaravadi RK, Schuchter LM, Carreno BM, Linette GP, Elder DE, Brody RM, Gimotty P, Miura JT, Karakousis GC, Xu X, Mitchell TC, Huang AC Antigen-specific profiling identifies T-bet(+) melanoma-specific CD8(+) T cells associated with response to neoadjuvant PD-1 blockade , Cancer Cell, 44(1): 2026
Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. , Science Advances, 11(3): 2025
Ma KL, Mitchell TC, Dougher M, Sharon CE Tortorello GN, elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Muira JT, Karakousis GC, Xu X. Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathologic response and recurrence-free survival. , Clin Cancer Res., 30(21): 2024
1., Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan P, Kier M, Laughlin AI, Kothari S, Giles JR. and Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney D, Xu, X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn A, Blank C, Weber J, Mitchell, TC, Farwell MD, Herati R*, Huang, AC* Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells , Cancer Cell, 42(9): 2024,1582-1597
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Matthew D, Chen Q, Khan O, Wu JE, ALcade V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali, DAA, Wherry EJ. LAB-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK expression and cytotoxicity. , Cell, 187(16): 2024,4336-4354
Mathew D, Maramareis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ, Minn AJ. Combined JAK Inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. , Science, 384(6702): 2024
